Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial

CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071

Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research